The Board of Directors approved the Un-Audited Financial Results for the Quarter Ended 30th June, 2026

CIN:L74110HP2004PLC027558 To Date: August 11, 2026 The Listing Department The Listing Department Bombay Stock Exchange Limited National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, C-1, Block-G Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Mumbai – 400001 Mumbai – 400051 Scrip Code: 532771 Trading Symbol: JHS Subject: Outcome of the Board Meeting held on Tuesday, August 11, 2026. Dear Sir, Pursuant to the provisions of Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, 11th August, 2026, inter alia, considered Approved the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended 30th June, 2026. The copies of Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended 30th June, 2026 along with Limited Review Reports received from the Statutory Auditors of the Company on the said results are enclosed herewith as Annexure – A. The Board Meeting commenced at 02:30 P.M. and concluded at 3:35 P.M. This information shall be made available on the website of the Company viz., www.svendgaard.com. Kindly take the same on records. Thanking You, For JHS Svendgaard Laboratories Limited Komal Jha Company Secretary & Compliance officer Encl: A/a V.K. KHOSLA & CO. Chartered Accountants INDIA Independent Auditor’s Review Report on Unaudited standalone Quarterly Financial Results and Year to Date Financial Results of JHS Svendgaard Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 (as amended’ To the Board of Directors of JHS Svendgaard Laboratories Limited 1 We have reviewed the accompanying statement of Unaudited Standalone Financial Results ('the Statement') of JHS Svendgaard Laboratories Limited (‘the Company') for the quarter ended 30 June 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Listing Regulations'). 2. The Statement, which is the responsibility of the Comparny's management and apptoved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement prineiples laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 (‘the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our Teview. 3. ‘We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, - 'Review of Interim Finaneial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial results are free of material misstatements. A review of interim financial information consists of making inquiries primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards ('Ind AS'") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thercunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 316-318 Second Floor, LSC Block-A6, DDA Market, Paschim Vihar, New Delhi-110063 Mob. : 9810268150, 9311905894 E-mail : amit@vkkhoslaco.com; kam_khosla@yahoo.co.in Emphasis of Matter There is no Emphasis of Matter in the report for the quarter ended June 30, 2026. 6. Other Matters There is no Other matters in the report for the quarter ended June 30, 2026. ¥or V.K. Khosla & Co. Chartered Accountants FRN 002283N " Amit Khosla (Partner) Memb No. 095943 UDIN: ) 6045443 NTQKR(aA2711 Place: New Delhi Date: Augusi 11, 2026 SAARD LABORATORIES LIMITED Regd. Office: Trilokpur Roud, Kheri (Kal Amb), Tehsil Nahan, Diste, Sivmour, Himachal Pradesh - 173030, Tndia CIN-L741 10HP204PLO027558 EMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 (Rs. in lakhs) Quarter Ended Quarter Ended Quarter Ended Year Ended 30 June 2026 31 Mar 2026 30 June 2025 31 Mareh 2026 S.No. Partienlars Unaudited Audited Unnudited Audited Revenue from operations 3.038.05 326957 234541 10.169.47 Other income 9,06 72.66 99.83 344.87 [Total income 3,047.11 334223 244524 10,514.34 2_[Bxpenses [Cost of materials consumed 187326 245085 142183 652085 [Purchases of stock-in-trade 12116 (18.48) 9.72 93,72 (Changes in inventorics of finished goods, work-in-progress and| 2316 0235 (1.64) (100.61) stock-in-trade [Einployee benefits expense 25744 310.87 266.53 112477 [Finance costs 284D 2242 15.67 85.68 [Depreciation and amortisation expenses 181,76 185.64 187,61 749.58 [Other expenses 525,63 646,00 52270 2,250.68 [Total expenses 3,040.82 3,640.15 238241 10,742.87 Profit/loss) before cxceptional items and tux (1-2) 629 (297.90) 62.62 (228.59) 4_|Exceptional items 5 5 5 5 5 _[Profit/(Loss) hefore tix_(3+4) 629 (@9791) 62.82 (228.59) 6 _|Tax expense/(income) [Current Tax S - - - - Deferred Tax (128.29) 1772 (@274) 77.74; [Tax for earlier years 2542 40,93 - 40,93 7_|Net Profit(Lass) for the period (5-6) 109.15 (356.56) 105,57 (191.73) 8 _|Other comprehensive income ~itoms that will not be rectassified to profit or loss 319 1221 2,96 1518 “Income tax relating (0 items that will not be reclassified to profil (0.99) (3.99) ©.77) (3.99) or loss [Total other comprehensive income 281 826 2.19 1123 9| Total comprehensive incame/ (loss) for the period (7+8) 11196 (348.29) 107.75 (180.50) 10 [Paid-up equity share capital ( Face value per sharc Rs. 10/-) 374058 74058 8,560.40 8,740.58 11_|Other Equity 12_|Earnings per cquity share ( Face value per share Rs. 10/-) Basic (Rs.) 013 ©42) [P (022) Diluted (Rs.) 013 (0.42) 012 (0.22) JHS SYENDGAARD LABORATORIE LIMITED Regd. Office: Trilokpur Road, Kheri (Kala-Amb), Tehsil Nahan, Distt, ‘mour, Himachal Pradesh - 173030, India CIN-L7411011P2004P1,C027558 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 Notes: 1 “The above unaudited standalone financial results have been reviewed and approved by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on 11 Aug 2026 2 T reh ce o gs nt ia tt iu ot no r ay n da u md eit ao sr u ro ef m et nhe t C pro im np cia pn ley s h oa fs t hc ea r Cr oie md p ao nu it e st he ( Ina du id ai nt Ao cf c ot uhe ns te i ns gt a Sn td aa nl do an re d s)fi n Ra un lc ei sa ,l 2r 0e 1s 5ul t (s I ndin Aa Sc )c o pr rd ea sn cc re ib ew di t uh n dt eh re Section 133 of the Companies Act, 2013, other accounting principles generally accepted in India and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SFB [Showing first 8,000 characters — download PDF for full document]